98%
921
2 minutes
20
Although transplantation of c-kit+ cardiac stem cells (CSCs) has been shown to alleviate left ventricular (LV) dysfunction induced by myocardial infarction (MI), the number of exogenous CSCs remaining in the recipient heart following transplantation and their mechanism of action remain unclear. We have previously developed a highly sensitive and accurate method to quantify the absolute number of male murine CSCs in female recipient organs after transplantation. In the present study, we used this method to monitor the number of donor CSCs in the recipient heart after intracoronary infusion. Female mice underwent a 60-min coronary occlusion followed by reperfusion; 2 days later, 100,000 c-kit+/lin- syngeneic male mouse CSCs were infused intracoronarily. Only 12.7% of the male CSCs present in the heart immediately (5 min) after infusion were still present in the heart at 24 h, and their number declined rapidly thereafter. By 35 days after infusion, only ∼ 1,000 male CSCs were found in the heart. Significant numbers of male CSCs were found in the lungs and kidneys, but only in the first 24 h. The number of CSCs in the lungs increased between 5 min and 24 h after infusion, indicating recirculation of CSCs initially retained in other organs. Despite the low retention and rapid disappearance of CSCs from the recipient heart, intracoronary delivery of CSCs significantly improved LV function at 35 days (Millar catheter). These results suggest that direct differentiation of CSCs alone cannot account for the beneficial effects of CSCs on LV function; therefore, paracrine effects must be the major mechanism. The demonstration that functional improvement is dissociated from survival of transplanted cells has major implications for our understanding of cell therapy. In addition, this new quantitative method of stem cell measurement will be useful in testing approaches of enhancing CSC engraftment and survival after transplantation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4013035 | PMC |
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0096725 | PLOS |
Arch Esp Urol
August 2025
Urology Department, Hospital and University Complex of Albacete, 02006 Albacete, Spain.
Background: Delayed graft function is a common situation that leads to increased long-term rates of graft rejection and loss. It is seen increasingly more often, as the use of kidneys from donors after controlled cardiac death has become more widespread. This study aimed to identify factors contributing to its onset and determine how these factors may influence graft survival.
View Article and Find Full Text PDFMedicine (Baltimore)
September 2025
Department of Emergency Medicine, Ajou University School of Medicine, Suwon, South Korea.
This study aimed to investigate the clinical course of brain death donors and admitted through the emergency department before organ procurement and early outcomes of kidney transplantation. We retrospectively reviewed the medical records of patients who visited a single tertiary emergency department with the final diagnosis of brain death and donor procurement between January 2013 and January 2022. Donors were categorized into 3 groups: brain hemorrhage, hanging, and other medical causes.
View Article and Find Full Text PDFTranspl Immunol
September 2025
Intensive Care, Royal Free Hospital, Hampstead, London, United Kingdom.
Background: Inflammatory injury in organ donors, particularly after brain death and during ischemia-reperfusion, contributes to graft dysfunction, rejection, and reduced survival. Statins, beyond their lipid-lowering role, exert pleiotropic anti-inflammatory and immunomodulatory effects, including IL-6 suppression, NF-κB inhibition, immune cell modulation, and potential alteration of exosome secretion.
Methods: Building upon this background, this narrative review synthesises preclinical and clinical evidence on pre-donation statin therapy in solid organ transplantation.
ESC Heart Fail
September 2025
Division of Heart Failure and Transplant, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Background: Patients with end-stage heart failure and chronic kidney disease requiring dual-organ transplantation (DOT) face significant challenges in utilizing durable mechanical circulatory support due to the risks associated with renal replacement therapies (RRTs) and multi-organ failure. Given the limited options available for long-term support in this patient population, there remains a critical need for alternative strategies to optimize end-organ function and bridge patients safely to transplant. With prolonged waitlist times for DOT, we present our experience with the Impella 5.
View Article and Find Full Text PDFTransplant Direct
September 2025
Laboratory for Transplantation Research, Department of Surgery, University Hospital Regensburg, Regensburg, Germany.
Extracorporeal photopheresis (ECP) is a safe and effective therapy with long-established indications in treating T cell-mediated immune diseases, including steroid refractory graft-versus-host disease and chronic rejection after heart or lung transplantation. The ECP procedure involves collecting autologous peripheral blood leucocytes that are driven into apoptosis before being reinfused intravenously. ECP acts primarily through in situ exposure of recipient dendritic cells and macrophages to apoptotic cells, which then suppress inflammation, promote specific regulatory T-cell responses, and retard fibrosis.
View Article and Find Full Text PDF